过去一年中添加的文章，按日期排序
[HTML][HTML] The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma
P Zhao, L Xu, H Zhu, W Ding, H Tang - Pathology-Research and Practice, 2024 - Elsevier
107 天前 - … of 8 months for the stage IV patient, and also longer than the … clinical results of
treating EGFR-T790M mutation with Osimertinib in the Asia-Pacific region [47]. Surely, the results …
treating EGFR-T790M mutation with Osimertinib in the Asia-Pacific region [47]. Surely, the results …
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic …
LIN Yicong, W Yue, XUE Qianqian, Z Qiang… - China …, 2024 - china-oncology.com
107 天前 - … lung cancers at risk for histologic transformation and inferior clinical outcomes[J].
J Thorac Oncol, 2019, 14(10): 1784-1793. [27] BITON J, MANSUET-LUPO A, PÉCUCHET N, …
J Thorac Oncol, 2019, 14(10): 1784-1793. [27] BITON J, MANSUET-LUPO A, PÉCUCHET N, …
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small …
108 天前 - … Clinical outcomes defined by the best tumor response are shown in S3 Table. CR
was achieved in 0.58% (n = 2) and PR in 31.88% (n = 110). More than half of the patients (n = …
was achieved in 0.58% (n = 2) and PR in 31.88% (n = 110). More than half of the patients (n = …
CLINICAL FACTORS PREDECTING T790M MUTATION IN NON-SMALL CELL LUNG CANCER PROGRESSED AFTER FIRST-AND SECOND-GENERATION TKI …
HH Hung, TC Minh, NTT Hoa… - Tạp chí Y học Việt …, 2024 - tapchiyhocvietnam.vn
113 天前 - … T790M mutation rate and clinical factors predicting the occurrence of acquired T790M
mutations … The results of our study also demonstrate that patients with a longer duration of …
mutations … The results of our study also demonstrate that patients with a longer duration of …
Efficacy and Adverse Events of Osimertinib Correlate With Blood Concentration of Osimertinib and Its Active Metabolites, AZ5104 and AZ7550
T Okuno, M Hongo, R Tanino, Y Tsubata… - C110. SURFING THE …, 2024 - atsjournals.org
123 天前 - … growth factor receptor [EGFR] T790M-positive non-small cell … (previously untreated,
EGFR mutation-positive advanced … [Results]There was a trend toward prolonged PFS in the …
EGFR mutation-positive advanced … [Results]There was a trend toward prolonged PFS in the …
Novel bronchoscopy method for molecular profiling of lung cancer: Targeted washing technique: A prospective cohort study
MH Kim, H Seong, H Jang, S Kim, W Yoo, SH Kim… - 2024 - researchsquare.com
132 天前 - … the T790M mutation detection rate by up to 10%. The accuracy of T790M mutation
… Our results suggest that mutational testing using TWF can be a reasonable option for …
… Our results suggest that mutational testing using TWF can be a reasonable option for …
[HTML][HTML] Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study …
Y Wang, Y Zhang, N Ren, F Li, L Lu, X Zhao… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
137 天前 - … The secondary EGFR T790M mutation accounts for 55.6% of acquired resistance.
The total number of patients with complications in initial biopsy was 25 (22.1%) and 37 (32.7…
The total number of patients with complications in initial biopsy was 25 (22.1%) and 37 (32.7…
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta …
L Guo, G Zhou, M Huang, K Tang… - The Clinical …, 2024 - Wiley Online Library
147 天前 - … <50%, indicating that these results were credible. Thus, … T790M mutation after
developing Osimertinib resistance had better clinical outcomes than patients who lost the T790M …
developing Osimertinib resistance had better clinical outcomes than patients who lost the T790M …
… ) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic …
149 天前 - … patients with T790M EGFR-mutant NSCLC. … -mutant NSCLC. Key secondary
endpoints include PFS and OS in all patients with NSCLC, ORR, DOR, patient-reported outcomes, …
endpoints include PFS and OS in all patients with NSCLC, ORR, DOR, patient-reported outcomes, …
Abstract CT055: Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation
R Wan, YF Chau, J Zhao, Z Liu, M Zhao, Y Zhao, X Dai… - Cancer Research, 2024 - AACR
149 天前 - … YK-029A in EGFR T790M mutated NSCLC was assessed by the investigators. Results:
A … By the cut-off date on Sep 12, 2023, 38 patients harbored EGFR T790M mutation were …
A … By the cut-off date on Sep 12, 2023, 38 patients harbored EGFR T790M mutation were …